HIGHFDA DRUG

Lupin Pharmaceuticals Recalls Sertraline Hydrochloride Tablets for Defective Seal

Lupin Pharmaceuticals recalled 52,128 bottles of Sertraline Hydrochloride Tablets on November 5, 2025. Consumers reported issues with defective seals that do not adhere to the bottles. The recall follows a Class II classification due to potential contamination risks.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
November 5, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
November 5, 2025
Hazard Level
HIGH
Brands
SERTRALINE HYDROCHLORIDE, Lupin Pharmaceuticals, Inc.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
SERTRALINE HYDROCHLORIDE, Lupin Pharmaceuticals, Inc.
Product type
Sertraline Hydrochloride Tablets
Model numbers
Lot # QB00865, exp. date Feb 2028
UPC codes
68180-351, 68180-352, 68180-353, 68180-978, 68180-986, 68180-992, 68180-351-08, 68180-351-06 +8 more
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    November 5, 2025

  2. Reported by FDA DRUG

    December 17, 2025

  3. RecallRadar source check

    December 24, 2025

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Defective container - seal not adhering to bottles

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Lupin Pharmaceuticals Inc. or your healthcare provider for guidance. Notification method: Letter

About This Product

Sertraline Hydrochloride Tablets are prescribed to treat depression, anxiety, and other mood disorders. Patients typically use this medication daily as part of their treatment regimen.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

Consumers who rely on Sertraline for mental health treatment face potential safety risks. The recall may cause inconvenience and necessitate obtaining replacements.

Practical Guidance

How to identify if yours is affected

  1. Check the lot number on your bottle against the recall notice.
  2. Confirm the expiration date is February 2028.
  3. Contact your healthcare provider for further instructions.

Where to find product info

The lot number and expiration date can usually be found on the bottom or side of the bottle.

What timeline to expect

Expect processing for refunds or replacements to take 4 to 6 weeks.

If the manufacturer is unresponsive

  • Follow up with customer service via phone or email.
  • Document all communication attempts.

How to prevent similar issues

  • Always check for recalls on medications before use.
  • Inspect packaging for any visible defects or damage before purchasing.
  • Consult with your pharmacist about medication safety.

Documentation advice

Keep receipts, correspondence regarding the recall, and photographs of the affected product.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

The recall involves Sertraline Hydrochloride Tablets USP, 100 mg, in 90-tablet bottles. Lot number QB00865 with an expiration date of February 2028 is affected. The product was distributed nationwide.

Key Facts

  • Recall date: November 5, 2025
  • Quantity recalled: 52,128 bottles
  • Lot number: QB00865, exp. date: Feb 2028
  • Class II recall due to high hazard risk

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product Details

Model Numbers
Lot # QB00865
exp. date Feb 2028
UPC Codes
68180-351
68180-352
68180-353
+13 more
Affected States
ALL
Report Date
December 17, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
HIGH

Lupin Pharmaceuticals Recalls Ganirelix Acetate Injection for Impurity Risk

Lupin Pharmaceuticals recalled 32,736 vials of Ganirelix Acetate Injection on November 13, 2025. The recall follows the discovery of impurities in the drug. Consumers and healthcare providers should stop using the product immediately to avoid health risks.

GANIRELIX ACETATE
Failed impurities/degradation
Read more